|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...29303132333435363738394041» |
- | SB-509 / Biogen
Trial completion: Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 26, 2012
P2, N=45, Completed, Sponsor: Sangamo Biosciences
Active, not recruiting --> Completed
- Xeomin (incobotulinumtoxinA) / Merz Pharma
New P2 trial: Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 25, 2012
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
- ursodeoxycholic acid / Generic mfg.
Enrollment closed: TUDCA-ALS: Efficacy and Tolerability of Tauroursodeoxycholic Acid in Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Mar 22, 2012
P2, N=26, Active, not recruiting, Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Balance Training for People With Multiple Sclerosis Using Nintendo Wii Fit (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=84, Completed, Sponsor: Örebro County Council
Recruiting --> Active, not recruiting Recruiting --> Completed
- || Enrollment change, Immunomodulating: Cognitive Effects of Immunomodulatory Drugs in MS (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=96, Completed, Sponsor: Sharon Lynch, MD
Recruiting --> Completed N=145 --> 96
- ||| Trial completion, Immunomodulating: Cognitive Effects of Immunomodulatory Drugs in MS (clinicaltrials.gov) - Mar 20, 2012
P=N/A, N=96, Completed, Sponsor: Sharon Lynch, MD
N=145 --> 96 Active, not recruiting --> Completed
- | Trial initiation date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Mar 14, 2012
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Mar 2012
- || Avonex (recombinant IFN-β-1a) / Biogen
Enrollment change: ASPECT: Avonex PEN Satisfaction and Patients Experience Clinical Trial (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=89, Completed, Sponsor: Biogen Idec
Initiation date: Oct 2011 --> Mar 2012 N=200 --> 89
- | Enrollment open: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - Mar 14, 2012
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
N=200 --> 89 Not yet recruiting --> Recruiting
- ||| Nerventra (laquinimod) / Active Biotech
Trial initiation date: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease (clinicaltrials.gov) - Mar 13, 2012
P2, N=211, Active, not recruiting, Sponsor: Teva Pharmaceutical Industries
Not yet recruiting --> Recruiting Initiation date: Jan 2006 --> Dec 2006
- | cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: PROMESS: Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2012
P3, N=138, Completed, Sponsor: University Hospital, Bordeaux
Initiation date: Jan 2006 --> Dec 2006 N=360 --> 138
- | cyclophosphamide / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Clinical: PROMESS: Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2012
P3, N=138, Completed, Sponsor: University Hospital, Bordeaux
N=360 --> 138 Active, not recruiting --> Completed
- Trial completion: Sensori-motor Integration Training in Multiple Sclerosis (clinicaltrials.gov) - Mar 13, 2012
P0, N=80, Completed, Sponsor: Universita di Verona
Active, not recruiting --> Completed Recruiting --> Completed
- Myobloc (rimabotulinumtoxin B) / Supernus Pharma, Eisai
Trial completion: Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 12, 2012
P2/3, N=20, Completed, Sponsor: The University of Texas Health Science Center at San Antonio
Recruiting --> Completed Active, not recruiting --> Completed
- | Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
New P2 trial: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Mar 11, 2012
P2, N=90, Recruiting, Sponsor: Hospices Civils de Lyon
- Trial completion: Safety Study of High Doses of Zinc in ALS Patients (clinicaltrials.gov) - Mar 8, 2012
P1/2, N=10, Completed, Sponsor: Phoenix Neurological Associates, LTD
Active, not recruiting --> Completed Recruiting --> Completed
- pioglitazone / Generic mfg.
Trial completion, P2a data, Combination therapy: Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 8, 2012
P2a, N=28, Completed, Sponsor: Phoenix Neurological Associates, LTD
Recruiting --> Completed Recruiting --> Completed
- Clinical: Functional Changes Following Percutaneous Venoplasty in Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 7, 2012
P=N/A, N=12, Not yet recruiting, Sponsor: University of Stirling
- ||| Rebif (human IFN-β-1a) / EMD Serono
Trial completion: Retrospective Cohort Study of Rebif® Use in Pediatric Multiple Sclerosis (MS) Subjects (REPLAY) (clinicaltrials.gov) - Mar 7, 2012
P=N/A, N=307, Completed, Sponsor: EMD Serono
Recruiting --> Completed Enrolling by invitation --> Completed
- sirolimus / Generic mfg.
Trial completion: Rapamycin In Angiomyolipomas In Patients With Tuberous Sclerosis (clinicaltrials.gov) - Mar 6, 2012
P4, N=18, Completed, Sponsor: Fundacio Puigvert
Enrolling by invitation --> Completed Active, not recruiting --> Completed
- Trial termination: Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=2, Terminated, Sponsor: Manish Mehta, MD
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- Enrollment change: Study To Evaluate Treating Chronic Cerebrospinal Venous Insufficiency (CCSVI) in Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=2, Terminated, Sponsor: Manish Mehta, MD
Active, not recruiting --> Terminated N=600 --> 2
- ||| Trial completion: MSSkin: Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=60, Completed, Sponsor: University of North Carolina, Charlotte
N=600 --> 2 Enrolling by invitation --> Completed
- | Enrollment change: CANNEBERGE: Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 29, 2012
P3, N=171, Completed, Sponsor: Rennes University Hospital
Enrolling by invitation --> Completed N=290 --> 171
- | Trial completion: CANNEBERGE: Cranberry for Prevention of Urinary Tract Infections in Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 29, 2012
P3, N=171, Completed, Sponsor: Rennes University Hospital
N=290 --> 171 Active, not recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment closed: Nilotinib in the Treatment of Systemic Sclerosis (clinicaltrials.gov) - Feb 29, 2012
P2a, N=10, Active, not recruiting, Sponsor: Hospital for Special Surgery, New York
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment open: LUPRON: GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases (clinicaltrials.gov) - Feb 28, 2012
P3, N=75, Recruiting, Sponsor: Joseph Mccune
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial completion: Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) (clinicaltrials.gov) - Feb 23, 2012
P1, N=52, Completed, Sponsor: The University of Texas Health Science Center, Houston
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Sativex (nabiximols) / Jazz
New P3 trial: NS-MSS: Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity (clinicaltrials.gov) - Feb 22, 2012
P3, N=45, Completed, Sponsor: Almirall, S.A.
- | Arcalyst (rilonacept) / Regeneron, Kiniksa
Biomarker, New P1/2 trial: IL1-TRAP, Rilonacept, in Systemic Sclerosis (clinicaltrials.gov) - Feb 22, 2012
P1/2, N=40, Recruiting, Sponsor: Boston University
- Enrollment change, Discordant: ARMS: AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS (clinicaltrials.gov) - Feb 20, 2012
P=N/A, N=3, Completed, Sponsor: The University of Texas Health Science Center, Houston
Active, not recruiting --> Completed N=30 --> 3
- | dexpramipexole (KNS-760704) / Knopp Biosciences, Biogen
New P1 trial: Dexpramipexole and Cimetidine Drug Drug Interaction (DDI) (clinicaltrials.gov) - Feb 20, 2012
P1, N=14, Completed, Sponsor: Biogen Idec
- Trial completion, Discordant: ARMS: AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS (clinicaltrials.gov) - Feb 20, 2012
P=N/A, N=3, Completed, Sponsor: The University of Texas Health Science Center, Houston
N=30 --> 3 Active, not recruiting --> Completed
- | dalfampridine / Generic mfg.
New P2 trial: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 16, 2012
P2, N=20, Completed, Sponsor: Acorda Therapeutics
- ||||| New P4 trial, Patient reported outcomes: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (clinicaltrials.gov) - Feb 14, 2012
P4, N=313, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- Tysabri (natalizumab) / Biogen, Royalty
Trial completion: NAPMS: Natalizumab Treatment of Progressive Multiple Sclerosis (clinicaltrials.gov) - Feb 14, 2012
P2, N=24, Completed, Sponsor: Rigshospitalet, Denmark
Active, not recruiting --> Completed Active, not recruiting --> Completed
- mycophenolate mofetil / Generic mfg.
Biomarker, Trial completion, Biopsy: Skin Biopsy Specimens as Biomarkers of Systemic Sclerosis and Response to Mycophenolate Mofetil (clinicaltrials.gov) - Feb 14, 2012
P=N/A, N=40, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| New P3 trial: A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 13, 2012
P3, N=87, Active, not recruiting, Sponsor: Hoffmann-La Roche
- ||||| Avonex (recombinant IFN-β-1a) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment change, Monotherapy: Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 8, 2012
P3, N=1800, Active, not recruiting, Sponsor: Biogen Idec
Recruiting --> Completed N=1500 --> 1800
- Trial withdrawal: A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS (clinicaltrials.gov) - Feb 7, 2012
P2, N=0, Withdrawn, Sponsor: CytRx
N=1500 --> 1800 Terminated --> Withdrawn
- Enrollment change: A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS (clinicaltrials.gov) - Feb 7, 2012
P2, N=0, Withdrawn, Sponsor: CytRx
Terminated --> Withdrawn N=390 --> 0
- Trial completion: Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions (clinicaltrials.gov) - Feb 6, 2012
P1, N=3, Completed, Sponsor: Institute for Neurodegenerative Disorders
N=390 --> 0 Active, not recruiting --> Completed
- atacicept (VT-001) / Vera Therap
P2 data, Enrollment change: ATAMS ext: Atacicept in Multiple Sclerosis Extension Study, Phase II (clinicaltrials.gov) - Feb 2, 2012
P2, N=68, Terminated, Sponsor: EMD Serono
Active, not recruiting --> Completed N=250 --> 68
- |||| Trial completion: TERIVA: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide (clinicaltrials.gov) - Feb 2, 2012
P2, N=128, Completed, Sponsor: Sanofi
N=250 --> 68 Active, not recruiting --> Completed
- |||| ceralifimod (ONO 4641) / Ono Pharma
Trial completion: DreaMS: A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Feb 2, 2012
P2, N=407, Completed, Sponsor: Ono Pharma USA Inc
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis (clinicaltrials.gov) - Feb 2, 2012
P=N/A, N=50, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| dronabinol (BX-1) / Bionorica
Trial completion: Efficacy and Safety of the Pain Relieving Effect of Dronabinol in Central Neuropathic Pain Related to Multiple Sclerosis (clinicaltrials.gov) - Feb 1, 2012
P3, N=240, Completed, Sponsor: Bionorica Research GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Tysabri (natalizumab) / Biogen, Royalty
Trial termination: SURPASS: Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (clinicaltrials.gov) - Feb 1, 2012
P3, N=84, Terminated, Sponsor: Biogen Idec
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study.
- || Betaseron (IFN-?-1b) / Bayer
Enrollment closed, Adherence: SEPLUS: Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (clinicaltrials.gov) - Jan 31, 2012
P=N/A, N=74, Active, not recruiting, Sponsor: Bayer
Active, not recruiting --> Terminated; Due to significantly slower than expected enrollment, the Sponsor decided to terminate the study. Recruiting --> Active, not recruiting
- methylprednisolone sodium succinate / Generic mfg.
New P2/3 trial: Optic Neuritis Recovery After Oral or IV Corticosteroids (clinicaltrials.gov) - Jan 30, 2012
P2/3, N=46, Recruiting, Sponsor: London Health Sciences Centre